Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
Alps Group (Nasdaq:ALPS) received a Nasdaq notice on May 15, 2026 for not meeting the $1.00 minimum bid price requirement after 30 consecutive business days below this level.
The notice has no immediate impact on listing, trading, operations, or financial condition. Alps has 180 days, until November 11, 2026, to regain compliance and may qualify for an additional 180 days, but faces potential delisting if the deficiency is not cured.
AI-generated analysis. Not financial advice.
Positive
- No immediate impact on Nasdaq listing, trading, operations, or financial condition
- Initial 180-day compliance period until November 11, 2026
- Potential additional 180-day period if other listing standards are met
- Company is evaluating options to regain Nasdaq bid price compliance
Negative
- Currently non-compliant with Nasdaq $1.00 minimum bid price rule 5450(a)(1)
- Risk of Nasdaq delisting if bid price deficiency is not cured
- Possible need for a reverse stock split to restore bid price compliance
- No assurance the company will regain or maintain Nasdaq listing compliance
News Market Reaction – ALPS
On the day this news was published, ALPS gained 0.14%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -12.2% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $193K to the company's valuation, bringing the market cap to $137.78M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 17 | Board appointment | Positive | -0.2% | Independent ex-EY partner added to board and key committees. |
| Feb 23 | Clinical data update | Positive | +2.3% | Published safety and tolerability data for autologous NK cell infusions. |
| Jan 30 | Pipeline expansion | Positive | +4.3% | Announced potential exosome pipeline expansion beyond CELESOME(+). |
| Jan 08 | CFO appointment | Positive | +2.0% | Named new CFO with extensive finance and accounting experience. |
Recent corporate and clinical updates with generally positive tone saw mixed immediate price reactions, with one governance update drawing a slight negative move.
Over the past months, Alps Group reported several governance and pipeline developments. Board and CFO appointments in January 2026 and April 2026 aimed at strengthening financial oversight, while clinical and pipeline updates in January and February 2026 highlighted early-stage NK cell and exosome work. Price reactions to these otherwise constructive announcements ranged from about flat to modestly positive, suggesting that prior news did not consistently trigger strong directional moves, in contrast to the more clearly risk-focused Nasdaq deficiency notice.
Market Pulse Summary
This announcement highlights that Alps Group fell below Nasdaq’s $1.00 minimum bid requirement over 30 consecutive business days and now faces a 180-day window, until November 11, 2026, to regain compliance. Historically, the company has focused on governance upgrades and early-stage clinical progress. Investors may watch how management addresses potential actions such as a reverse split, alongside execution on its biotech and wellness platform, to manage ongoing listing and financing risks.
Key Terms
nasdaq listing rules 5450(a)(1) regulatory
minimum bid price regulatory
reverse stock split financial
delisting regulatory
AI-generated analysis. Not financial advice.
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced that on May 15, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of
The notification has no immediate effect on the listing or trading of the Company’s ordinary shares on Nasdaq, and it does not affect the Company’s current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company’s securities will be subject to delisting.
The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
About Alps Group
Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
212-896-1233
alps@kcsa.com
